Last reviewed · How we verify

infliximab infusion; AZA placebo caps

Centocor Ortho Biotech Services, L.L.C. · Phase 3 active Biologic

infliximab infusion; AZA placebo caps is a TNF-alpha inhibitor Biologic drug developed by Centocor Ortho Biotech Services, L.L.C.. It is currently in Phase 3 development for Rheumatoid arthritis, Crohn's disease, Ulcerative colitis.

Infliximab is a chimeric monoclonal antibody that binds to tumor necrosis factor-alpha (TNF-alpha), preventing its interaction with cell surface TNF receptors and thereby inhibiting the inflammatory response.

Infliximab is a chimeric monoclonal antibody that binds to tumor necrosis factor-alpha (TNF-alpha), preventing its interaction with cell surface TNF receptors and thereby inhibiting the inflammatory response. Used for Rheumatoid arthritis, Crohn's disease, Ulcerative colitis.

At a glance

Generic nameinfliximab infusion; AZA placebo caps
SponsorCentocor Ortho Biotech Services, L.L.C.
Drug classTNF-alpha inhibitor
TargetTNF-alpha
ModalityBiologic
Therapeutic areaImmunology
PhasePhase 3

Mechanism of action

Infliximab is a chimeric monoclonal antibody that targets tumor necrosis factor-alpha (TNF-alpha), a cytokine involved in systemic inflammation. By binding to TNF-alpha, infliximab prevents the interaction between TNF-alpha and its receptors on the surface of immune cells, thereby inhibiting the inflammatory response. This mechanism of action is thought to contribute to the therapeutic effects of infliximab in treating various inflammatory conditions.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about infliximab infusion; AZA placebo caps

What is infliximab infusion; AZA placebo caps?

infliximab infusion; AZA placebo caps is a TNF-alpha inhibitor drug developed by Centocor Ortho Biotech Services, L.L.C., indicated for Rheumatoid arthritis, Crohn's disease, Ulcerative colitis.

How does infliximab infusion; AZA placebo caps work?

Infliximab is a chimeric monoclonal antibody that binds to tumor necrosis factor-alpha (TNF-alpha), preventing its interaction with cell surface TNF receptors and thereby inhibiting the inflammatory response.

What is infliximab infusion; AZA placebo caps used for?

infliximab infusion; AZA placebo caps is indicated for Rheumatoid arthritis, Crohn's disease, Ulcerative colitis, Psoriatic arthritis, Ankylosing spondylitis.

Who makes infliximab infusion; AZA placebo caps?

infliximab infusion; AZA placebo caps is developed by Centocor Ortho Biotech Services, L.L.C. (see full Centocor Ortho Biotech Services, L.L.C. pipeline at /company/centocor-ortho-biotech-services-l-l-c).

What drug class is infliximab infusion; AZA placebo caps in?

infliximab infusion; AZA placebo caps belongs to the TNF-alpha inhibitor class. See all TNF-alpha inhibitor drugs at /class/tnf-alpha-inhibitor.

What development phase is infliximab infusion; AZA placebo caps in?

infliximab infusion; AZA placebo caps is in Phase 3.

What are the side effects of infliximab infusion; AZA placebo caps?

Common side effects of infliximab infusion; AZA placebo caps include Infusion reactions, Nausea, Headache, Fatigue, Musculoskeletal pain.

What does infliximab infusion; AZA placebo caps target?

infliximab infusion; AZA placebo caps targets TNF-alpha and is a TNF-alpha inhibitor.

Related